CAR T Bridging for MM: Module

CME

The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 17, 2023

Expiration: July 16, 2024

Thomas G. Martin
Thomas G. Martin, MD

Activity

Progress
1
Course Completed

Which of the following is not a goal of bridging therapeutic strategies prior to CAR T-cell therapy in the real-world treatment of patients with MM?

Which of the following factors in a patient with relapsed/refractory (R/R) MM is least indicative of a need for bridging therapy while awaiting a CAR T-cell manufacturing slot?

Which of the following treatment regimens would be best to avoid as a bridging therapy for a patient with R/R MM awaiting a CAR T-cell manufacturing slot?